Lichenoid drug eruption associated with imatinib mesylate: A side effect to recognize.
Alheyasat Rihame R, Soughi Meryem M, Elousrouti Layla Tahiri LT, Bejja Ikram I et al.
Johnson & Johnson Services, Inc. · VIPR1 · 小分子
aviptadil + phentolamine mesylate 是一种小分子,由Johnson & Johnson Services, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。
| 商品名 | Invicorp, VIP, Senetek, Resurgam |
| 公司 | Johnson & Johnson Services, Inc. |
| 药物类别 | 小分子 |
| 分子靶点 | VIPR1 |
| 给药途径 | Injectable (Others), Intravenous (IV) |
| 状态 | Approved |
aviptadil + phentolamine mesylate 作用于 1 个分子靶点:
| VIPR1 | vasoactive intestinal peptide receptor 1 (PACAP-R2, V1RG) |
aviptadil + phentolamine mesylate 针对 1 个适应症,涉及 1 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Reproductive system and breast disorders | Erectile dysfunction | ✓ Approved |
Alheyasat Rihame R, Soughi Meryem M, Elousrouti Layla Tahiri LT, Bejja Ikram I et al.
Liang Liling L, Zhang Jingjing J, Zhang Ying Y
As the most prevalent neurodegenerative disorder, Alzheimer's disease (AD) poses a pressing need for novel therapeutic targets. This study was designed to address this gap by screening and validating druggable genetic targets nominally associated with AD through an integrative multi-omics approach. Mendelian randomization (MR) screened the druggable genome. GTEx eQTL data and differential expression analysis identified core candidates. SMR, GSMR, and cross-tissue eQTL validation assessed putative causal effects and cross-tissue generalizability. Single-cell RNA sequencing (scRNA-seq) dissected cell type-specific expression. Virtual knockout combined with cell-cell communication analysis elucidated regulatory mechanisms. Mediation analysis evaluated Cerebrospinal fluid (CSF) metabolite involvement, and molecular docking screened therapeutic agents. Genetically predicted TUBB2A expression was nominally associated with AD risk. Virtual knockout analysis revealed that TUBB2A deficiency induced significant upregulation of SLC1A3 and HIF3A, suggesting compensatory glutamate clearance and hypoxic stress responses. Nominal mediation analysis suggested that the CSF metabolite orotidine may be involved in the TUBB2A-AD association. Molecular docking revealed high binding affinity between Eribulin mesylate and TUBB2A. This study identifies TUBB2A as a priority candidate gene for further validation in AD, proposes a potential role for orotidine in TUBB2A-related AD susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies. susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies.
Xu Ziyi Z, Liang Shuyu S, Wang Zhaopeng Z, Wan Daicao D et al.
Chronic diabetic wound management remains challenging because bacterial infection, persistent inflammation, excessive exudate, and impaired vascularization form a vicious cycle. Here, we report a wound-fluid-triggered multifunctional self-gelling powder (MSP) based on a carbohydrate-containing matrix integrating rapid hemostasis with wound-microenvironment regulation and tissue regeneration. MSP incorporates quaternized chitosan (QCS), tannic acid (TA), Ca2+, and deferoxamine mesylate (DFO) within a hydrophilic ionic PAA-co-SPM framework. Upon contact with blood or wound exudate, MSP rapidly absorbs fluid and undergoes an in situ powder-to-gel transition, forming a conformal adhesive hydrogel that seals irregular wound surfaces. The resulting interfacial transition promotes hemostasis through physical occlusion, QCS-mediated blood-cell adhesion and aggregation, and Ca2+-assisted coagulation. QCS synergizes with TA and DFO to reduce bacterial burden and oxidative stress, suppress inflammation, and promote HIF-1α-associated angiogenesis, thereby facilitating diabetic wound repair. Moreover, saline-responsive disassembly enables gentle removal upon irrigation and may reduce tissue disruption and rebleeding during dressing changes. Overall, MSP integrates rapid hemostasis, wound-microenvironment modulation, tissue regeneration, and gentle removal, providing a materials-based strategy for the sequential management of acute bleeding and chronic diabetic wounds.
Arleo Timothy T, Volin Joshua J, Abunimer Luma L, Bello Hernan R HR et al.
Gastrointestinal stromal tumors (GISTs) have evolved from historically misclassified smooth muscle tumors to a distinct disease entity, defined by gain-of-function mutations in KIT or PDGFRA proto-oncogenes. The advent of targeted therapy for this entity in the form of a tyrosine kinase inhibitor (TKI), imatinib mesylate, has transformed the treatment for GISTs, reducing recurrence and improving survival in patients with advanced disease. Radiologists play a critical role in initial lesion identification, surgical planning, and posttherapy surveillance, with cross-sectional imaging (CT and MRI) being vital in characterizing tumor features such as endophytic or exophytic nature, pseudocapsule, ulceration, necrosis, and changes in enhancement. Incorporating the Choi criteria into routine practice further refines response assessment, guiding adjustments in therapeutic strategy. A multidisciplinary approach is essential for optimal GIST management, requiring close collaboration between surgeons, oncologists, pathologists, and radiologists to establish a diagnosis, determine resectability, consider neoadjuvant or adjuvant TKIs, and monitor for disease recurrence (with imaging intervals tailored to risk classification). Future directions involve greater incorporation of molecular profiling to personalize treatments and the integration of newer-generation TKIs for imatinib-resistant cases, highlighting the continued importance of interdisciplinary coordination.
Edwards Andrew G AG, Petroski Jack J, Patel Raj R, Koyfman Sergey S
BACKGROUND Primary synovial sarcoma of the thyroid gland (PSST) is an exceptionally rare and aggressive neoplasm. Twenty-one cases have been reported in the literature to date, making this the 22nd reported occurrence. This report presents the case of a 47-year-old woman with PSST confirmed by SS18 gene fusion on fluorescence in situ hybridization (FISH), who subsequently developed pulmonary metastasis and doxorubicin-induced congestive heart failure, illustrating the aggressive clinical course of this entity. CASE REPORT We report the case of a 47-year-old woman presenting with dysphagia and a left-sided neck mass. Initial FNA was non-diagnostic; repeat FNA raised concern for a spindle cell neoplasm. Left hemithyroidectomy was performed with negative margins, and SS18 gene fusion was confirmed by FISH, establishing the diagnosis of PSST. Following multidisciplinary review, adjuvant chemotherapy was deferred and neck radiation was administered. Pulmonary metastasis was discovered 6 months postoperatively. The patient received eribulin mesylate and subsequent palliative doxorubicin, and her case was complicated by doxorubicin-induced congestive heart failure. She subsequently developed progressive systemic metastatic disease, including brain and bone involvement, and died of the disease 65 months after initial presentation. CONCLUSIONS This case demonstrates that SS18 FISH confirmation is essential when FNA is non-diagnostic for a thyroid spindle cell mass. Despite negative margins and adjuvant radiation, early pulmonary metastasis and ultimately fatal systemic metastatic disease to the brain and bone occurred, underscoring the aggressive clinical course of PSST. Doxorubicin-induced cardiac toxicity further illustrates the systemic therapy burden. BCL-2-directed strategies remain investigational. Complete surgical resection with negative margins is the cornerstone of management.
Crossland David D, Kesireddy Nithin N, Acton Tayler T, Fillerup Ian I et al.
Prior studies have indicated that peripheral administration of vasopressors, particularly norepinephrine, can be considered safe, with local complications occurring in 0% to 1.8% of patients. Our study further explored the local skin complications from peripheral vasopressor administration treated with phentolamine in a large health care system. A retrospective chart review was performed on patients who received phentolamine for effects of local infiltration of pressors. Data were collected for demographics, vasopressor dose and duration of use, phentolamine dose and time after extravasation until administration, peripheral intravenous characteristics, as well as outcomes such as length of stay and mortality. Data on patients who did and did not require central venous catheter placement postextravasation were compared. Of 92 patients with infiltrated vasopressor intravenous access who required phentolamine, the mean age was 69, with 65% being female and a mean body mass index of 28 kg/m2. The most common sites of intravenous access were the antecubital fossa (33%) and forearm (27%). Mean number of hours prior to extravasation of peripheral vasopressors requiring phentolamine administration was 21 hours. Mean number of minutes prior to phentolamine administration after extravasation was 131 minutes. Seventy-six percent of patients did not any have significant ischemic tissue injury with extravasation, and 24% of patients had only minor bruising and erythema. Two significant reactions occurred, including deep vein thrombosis and local skin necrosis. Fifty-two percent of patients required a subsequent central venous line placement. The mean length of stay was 5.4 days in the intensive care unit and 11.8 days in the hospital, and in-patient mortality was 17%. In our large cohort of patients with extravasation from peripheral vasopressors managed with local phentolamine administration, severe tissue skin or soft tissue injury was rare.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →